STING1 and neoplasm: These include induction of the release of DNA and RNA into cytoplasm; induced Type I IFN responses; promotion of the release of danger signals such as damage-associated molecular patterns (DAMPs) [71,72]; activation of the STING signaling pathway [73]; induction of increased expression of major histocompatibility complex class I (MHC I) proteins on the cancer cell surface [71,74]; and enhanced presentation of tumor-associated antigens to immune systems via antigen presenting cells [71,74,75,76].